Jerome De Vente

695 total citations
9 papers, 440 citations indexed

About

Jerome De Vente is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Jerome De Vente has authored 9 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 5 papers in Virology and 2 papers in Hepatology. Recurrent topics in Jerome De Vente's work include HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Jerome De Vente is often cited by papers focused on HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and HIV/AIDS Research and Interventions (4 papers). Jerome De Vente collaborates with scholars based in United States, Belgium and Canada. Jerome De Vente's co-authors include Richard W. Hanson, Jeong‐Ho Yun, Anthony Wynshaw‐Boris, Tristan Wagner, Fritz Rottman, John W. Bloom, M.M. McGrane, William Spreen, Britt Stancil and David A. Margolis and has published in prestigious journals such as Journal of Biological Chemistry, The Lancet Infectious Diseases and AIDS.

In The Last Decade

Jerome De Vente

9 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerome De Vente United States 6 195 148 142 110 78 9 440
María Gracia Mateo Spain 12 152 0.8× 133 0.9× 78 0.5× 28 0.3× 24 0.3× 23 336
Jianhui Fan China 11 44 0.2× 133 0.9× 102 0.7× 17 0.2× 37 0.5× 23 446
Jordi P Guallar Spain 7 163 0.8× 142 1.0× 94 0.7× 35 0.3× 17 0.2× 9 391
Aidan S. Hancock United States 10 87 0.4× 175 1.2× 81 0.6× 33 0.3× 50 0.6× 12 423
Erik Abner Estonia 11 103 0.5× 147 1.0× 145 1.0× 62 0.6× 34 0.4× 16 388
Irene Fernández Spain 12 68 0.3× 66 0.4× 167 1.2× 21 0.2× 10 0.1× 25 352
Daryl Humes United States 13 168 0.9× 186 1.3× 119 0.8× 45 0.4× 10 0.1× 23 632
Rosa García Spain 10 63 0.3× 52 0.4× 47 0.3× 28 0.3× 44 0.6× 15 334
Consuelo Viladés Spain 17 255 1.3× 335 2.3× 108 0.8× 17 0.2× 29 0.4× 39 563
Ralf Winzer Germany 7 122 0.6× 77 0.5× 121 0.9× 55 0.5× 172 2.2× 15 374

Countries citing papers authored by Jerome De Vente

Since Specialization
Citations

This map shows the geographic impact of Jerome De Vente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerome De Vente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerome De Vente more than expected).

Fields of papers citing papers by Jerome De Vente

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerome De Vente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerome De Vente. The network helps show where Jerome De Vente may publish in the future.

Co-authorship network of co-authors of Jerome De Vente

This figure shows the co-authorship network connecting the top 25 collaborators of Jerome De Vente. A scholar is included among the top collaborators of Jerome De Vente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerome De Vente. Jerome De Vente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Moucheraud, Corrina, et al.. (2023). Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study. BMC Health Services Research. 23(1). 156–156. 7 indexed citations
2.
Sutton, Kenneth, Jerome De Vente, Roger LeBlanc, et al.. (2022). Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study. Open Forum Infectious Diseases. 9(4). ofac067–ofac067. 2 indexed citations
3.
Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2021). Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. AIDS. 36(2). 195–203. 25 indexed citations
4.
Towner, William, Edwin DeJesus, Shannon Schrader, et al.. (2020). 1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants. Open Forum Infectious Diseases. 7(Supplement_1). S542–S543. 4 indexed citations
5.
Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2020). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open Forum Infectious Diseases. 7(Supplement_1). S186–S187. 1 indexed citations
6.
Margolis, David M., Kenneth Sutton, Jerome De Vente, et al.. (2019). 2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results. Open Forum Infectious Diseases. 6(Supplement_2). S66–S67. 8 indexed citations
8.
McHenry, Christopher R., et al.. (1997). Acute suppurative thyroiditis and necrosis of the thyroid gland: A rare endocrine manifestation of acquired immunodeficiency syndrome. Surgery. 121(5). 593–596. 24 indexed citations
9.
McGrane, M.M., Jerome De Vente, Jeong‐Ho Yun, et al.. (1988). Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice.. Journal of Biological Chemistry. 263(23). 11443–11451. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026